How Pharma Firms Using AI Should Navigate Regulatory Submissions

Global regulators have yet to develop hard and fast rules for the use of artificial intelligence in drug development. Until they do, pharma companies should be guided by transparency and best practice principles when preparing submissions, a consultant says.